Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis.
Dimethyl fumarate
Efficacy
Multiple sclerosis
Safety
Teriflunomide
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
20
02
2020
accepted:
28
05
2020
revised:
23
05
2020
pubmed:
9
6
2020
medline:
21
5
2021
entrez:
8
6
2020
Statut:
ppublish
Résumé
The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment. To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients. Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were "time-to-first-relapse", "time-to-Magnetic-Resonance-Imaging (MRI)-activity" and "time-to-disability-progression". 1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (p < 0.001 for all). Patients on DMF had a higher number of relapses and radiological activity (p < .05) at baseline. Time-varying Cox-model for the event "time-to-first relapse" revealed that no differences were found between the two groups in the first 38 months of treatment (HR Patients on DMF had higher relapse-free survival time than TRF group after the first 38 months on therapy.
Sections du résumé
BACKGROUND
BACKGROUND
The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment.
OBJECTIVES
OBJECTIVE
To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients.
MATERIALS AND METHODS
METHODS
Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were "time-to-first-relapse", "time-to-Magnetic-Resonance-Imaging (MRI)-activity" and "time-to-disability-progression".
RESULTS
RESULTS
1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (p < 0.001 for all). Patients on DMF had a higher number of relapses and radiological activity (p < .05) at baseline. Time-varying Cox-model for the event "time-to-first relapse" revealed that no differences were found between the two groups in the first 38 months of treatment (HR
CONCLUSIONS
CONCLUSIONS
Patients on DMF had higher relapse-free survival time than TRF group after the first 38 months on therapy.
Identifiants
pubmed: 32506391
doi: 10.1007/s00415-020-09959-1
pii: 10.1007/s00415-020-09959-1
doi:
Substances chimiques
Crotonates
0
Hydroxybutyrates
0
Immunosuppressive Agents
0
Nitriles
0
Toluidines
0
teriflunomide
1C058IKG3B
Dimethyl Fumarate
FO2303MNI2
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3008-3020Investigateurs
Giovanna Borriello
(G)
Paola Grossi
(P)
Antonio Carotenuto
(A)
Ernesto Siena
(E)
Elena Tsantes
(E)
Alessia Giugno
(A)
Gian Marco Abbadessa
(GM)
Clara Grazia Chisari
(CG)